Experimental cancer drug GEN1057 trial ends early
NCT ID NCT06573294
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
-
National Cancer Center, Tsukiji 5-1-1
Tokyo, Japan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
Start Madrid Centro Integral Oncologico Clara Campal CIOCC
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.